Coronary sinus blood sampling: An insight into local cardiac pathophysiology and treatment?

European Heart Journal

Volumn 28, Issue 8, 2007, Pages 929-940

  Jaumdally, Rumi ^a   Varma, Chetan ^a   Macfadyen, Robert J ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Circulating factors; Coronary sinus; Myocardial ischaemia

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIN 1; GROWTH FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; AORTA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CORONARY SINUS; ENDOTHELIAL DYSFUNCTION; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYNDROME X; THROMBOGENESIS; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VENOUS BLOOD;

C-REACTIVE PROTEIN; COLLATERAL CIRCULATION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; ENDOTHELIUM, VASCULAR; HEART CATHETERIZATION; HUMANS; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548308845     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehm015     Document Type: Review

References (127)

1. British Heart Foundation Fact; 2000. http://file04/www.bhf.org. uk/professionals/uploaded/apr00.pdf.
2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-1442.
3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Atherosclerosis 2004;173:381-391.
4. Liu JL, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart 2002;88:597-603.
5. Anderson KM, Odell PM, Wilson PWF, Kannel PW. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-298.
6. Crittenden MD. Intraoperative metabolic monitoring of the heart: I. Clinical assessment of coronary sinus metabolites. Ann Thorac Surg 2001;72:S2220-S2226.
7. Knight BP, Gersh BJ, Carlson MD, Friedman PA, McNamara RL, Strickberger SA, Tse HF, Waldo AL; American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias); Quality of Care and Outcomes Research Interdisciplinary Working Group; Heart Rhythm Society; AHA Writing Group. Role of permanent pacing to prevent atrial fibrillation: science advisory from the American Heart Association C. Circulation 2005;111:240-243.
8. Baim DS, Rothman MT, Harrison DC. Improved catheter for regional coronary sinus flow and metabolic studies. Am J Cardiol 1980;46:997-1000.
9. Winters KJ, Lasala JM, Eisenberg PR, Smith SC, Sewall DJ, Shelton ME. Modified heparin-bonded catheter for cannulation of the coronary sinus from the femoral vein. Cathet Cardiovasc Diagn 1996;39:433-437.
10. Ueno T, Kai H, Ikeda H, Matsumoto T, Murohara T, Haramaki N, Eguchi H, Kato A, Takajo Y, Onitsuka I, Imaizumi T. Coronary sinus long sheath catheter system: a new device for transfemoral coronary sinus catheterization. Heart Vessels 1999;14:201-204.
11. Vaseghi M, Cesario D, Ji S, Shannon KM, Wiener I, Boyle NG, Fonarow GC, ValderrÁbano M, Shivkumar K. Visualization using LCA injection. Pacing Clin Electrophysiol 2005;28:185-190.
12. Lantos J, Temes G, Gobolos L, Jaberansari MT, Roth E. Is peripheral blood a reliable indicator of acute oxidative stress following heart ischemia and reperfusion? Med Sci Monit 2001;7:1166-1170.
13. Crea F, Lanza GA. Angina pectoris and normal coronary arteries: cardiac syndrome X. Heart 2004;90:457-463.
14. Cannon RO, Epstein SE. 'Microvascular angina' as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol 1988;61:1338-1343.
15. Buchthal SD, den Hollander JA, Merz CNB, Merz CN, Rogers WJ, Pepine CJ, Reichek N, Sharaf BL, Reis S, Kelsey SF, Pohost GM. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med 2000;342:829-835.
16. Galassi AR, Crea F, Araujo LI, Lammertsma AA, Pupita G, Yamamoto Y, Rechavia E, Jones T, Kaski JC, Maseri A. Comparison of myocardial blood flow in syndrome X and one-vessel coronary artery disease. Am J Cardiol 1993;72:134-142.
17. Buffon A, Rigattieri S, Santini SA, Ramazzotti V, Crea F, Giardina B, Maseri A. Myocardial ischemia-reperfusion damage after pacing-induced tachycardia in patients with cardiac syndrome X. Am J Physiol Heart Circ Physiol 2000;279:H2627-H2633.
18. Lanza GA, Lüscher TF, Pasceri V, Shaw SG, Buffon A, Montenero AS, Crea F, Maseri A. Effects of atrial pacing on arterial and coronary sinus endothelin-1 levels in syndrome X. Am J Cardiol 1999;84:1187-1191.
19. Oshima S, Yasue H, Ogawa H, Okumura K, Matsuyama K. Fibrinopeptide A is released into the coronary circulation after coronary spasm. Circulation 1990;82:2222-2225.
20. Kaikita K, Ogawa H, Yasue H, Sakamoto T, Suefuji H, Sumida H, Okumura K. Soluble P-selectin is released into the coronary circulation after coronary spasm. Circulation 1995;92:1726-1730.
21. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 1993;328:659-1664.
22. Greenberg MA, Grose RM, Neuburger N, Silverman R, Strain JE, Cohen MV. Impaired coronary vasodilator responsiveness as a cause of lactate production during pacing-induced ischemia in patients with angina pectoris and normal coronary arteries. J Am Coll Cardiol 1987;9:743-751.
23. Camici PG, Marraccini P, Lorenzoni R, Buzzigoli G, Pecori N, Perissinotto A, Ferrannini E, L'Abbate A, Marzilli M. Coronary hemodynamics and myocardial metabolism in patients with syndrome X: response to pacing stress. J Am Coll Cardiol 1991;17:1461-1470.
24. Goldberg S, Lam W, Mudge G, Green LH, Kushner F, Hirshfeld JW, Kastor JA. Coronary hemodynamic and myocardial metabolic alterations accompanying coronary spasm. Am J Cardiol 1979;43:481-487.
25. Mohri M, Ichiki T, Hirooka Y, Takeshita A. Endogenous nitric oxide prevents myocardial ischemia in patients with hypertension and left ventricular hypertrophy. Am Heart J 2002;143:684-689.
26. Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and clinical therapeutic approaches. Vasc Med 1998;3:231-239.
27. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-2012.
28. Drexler H. Factors involved in the maintenance of endothelial function. Am J Cardiol 1998;82:3S-4S.
29. Kinlay S, Behrendt D, Wainstein M, Beltrame J, Fang JC, Creager MA, Selwyn AP, Ganz P. The role of endothelin-1 in the constriction of human atherosclerotic coronary arteries. Circulation 2001;104:1114-1118.
30. Rubbo H, Trostchansky A, Botti H, Batthyany C. Interactions of nitric oxide and peroxynitrite with low-density lipoprotein. Biol Chem 2002;383:547-552.
31. Pernow J, Kaijser L, Lundberg JM, Ahlborg G. Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 1996;94:2077-2082.
32. Lerman A, Holmes DR Jr, Bell MR, Garratt KN, Nishimura RA, Burnett JC Jr. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995;92:2426-2431.
33. Ludman PF, Maseri A, Clark P, Davies GJ. Effects of calcitonin gene-related peptide on normal and atheromatous vessels and on resistance vessels in the coronary circulation in humans. Circulation 1991;84:1993-2000.
34. Mezaki T, Matsubara T, Hori T, Higuchi K, Nakamura A, Nakagawa I, Imai S, Ozaki K, Tsuchida K, Nasuno A, Tanaka T, Kubota K, Nakano M, Miida T, Aizawa Y. Plasma levels of soluble thrombomodulin, C-reactive protein, and serum amyloid A protein in the atherosclerotic coronary circulation. Jpn Heart J 2003;44:601-612.
35. Matsubara T, Ishibashi T, Hori T, Ozaki K, Mezaki T, Tsuchida K, Nasuno A, Kubota K, Tanaka T, Miida T, Aizawa Y, Nishio M. Association between coronary endothelial dysfunction and local inflammation of atherosclerotic coronary arteries. Mol Cell Biochem 2003;249:67-73.
36. Kruger D, Sheikhzadeh A, Giannitsis E, Stierle U. Cardiac release and kinetics of endothelin after severe short-lasting myocardial ischemia. J Am Coll Cardiol 1997;30:942-946.
37. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395.
38. Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998;98:2108-2116.
39. Lim HS, Blann AD, Chong AY, Freestone B, Lip GY. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 2004;27:2918-2924.
40. El-Gendi H, Violaris AG, Foale R, Sharma HS, Sheridan DJ. Endogenous, local, vascular endothelial growth factor production in patients with chronic total coronary artery occlusions: further evidence for its role in angiogenesis. Heart 2002;87:158-159.
41. Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, Redwood SR, Pearson JD, Marber MS. Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support. Circulation 2004;109:2986-2992.
42. Ito BR, Roth DM, Chenoweth DE, Lefer AM, Engler RL. Thromboxane is produced in response to intracoronary infusions of complement C5a in pigs. Cyclooxygenase blockade does not reduce the myocardial ischemia and leukocyte accumulation. Circ Res 1989;65:1220-1232.
43. Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N. Serum hepatocyte growth factor predicts ventricular remodeling following myocardial infarction. Circ J 2002;66:1003-1007.
44. Fuster V, Badimon JJ. Clinical therapeutic approaches. Vasc Med 1998;3:231-239.
45. Loscalzo J. The relation between atherosclerosis and thrombosis. Circulation 1992;86:95-99.
46. Cella G, Zahavi J, DeHaas HA, Kakkar VV. Beta thromboglobulin, platelet production time and platelet function in vascular disease. Br J Haematol 1979;43:127-136.
47. Lam JY, Latour JG, Lesperance J, Water D. Platelet aggregation, coronary artery disease progression and future coronary events. Am J Cardiol 1994;73:333-338.
48. Rasi V, Torstila I, Ikkata E. Beta thromboglobulin in acute myocardial. Acta Med Scand 1980;642:85-91.
49. Marcella JJ, Nichols AB, Johnson LL, Owen J, Reison DS, Kaplan KL, Cannon PJ. Exercise-induced myocardial ischemia in patients with coronary artery disease: lack of evidence for platelet activation or fibrin formation in peripheral venous blood. J Am Coll Cardiol 1983;1:1185-1193.
50. Martin JL, Fisher CA, Untereker WJ, Laskey WK, Hirshfeld JW Jr, Harken AH, Addonizio VP. Effect of high dose aspirin on coronary hemodynamics during pacing-induced myocardial ischemia. J Am Coll Cardiol 1985;5:210-215.
51. Berger HJ, Zaret BL, Speroff L, Cohen LS, Wolfson S. Cardiac prostaglandin release during myocardial ischemia induced by atrial pacing in patients with coronary artery disease. Am J Cardiol 1977;39:481- 486.
52. Montalescot G, Drobinski G, Maclouf J, Maillet F, Salloum J, Ankri A, Kazatchkine M, Eugene L, Thomas D, Grosgogeat Y. Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina pectoris. Circulation 1991;84:2054-2062.
53. Montalescot G, Maclouf J, Drobinski G, Mencia-Huerta JM, Ankri A, Grosgogeat Y, Thomas D. Lack of platelet-activating factor release during reversible myocardial ischaemia. Eur Heart J 1992;13:1641-1644.
54. Montalescot G, Maclouf J, Drobinski G, Salloum J, Grosgogeat Y, Thomas D. Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low dose aspirin. J Am Coll Cardiol 1994;24:33-38.
55. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, Fox KA, Boon NA. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 2001;103:1936-1941.
56. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-2476.
57. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002;106:2767-2770.
58. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000;20:1595-1599.
59. Furuhashi M, Ura N, Moniwa N, Shinshi Y, Kouzu H, Nishihara M, Kokubu N, Takahashi T, Sakamoto K, Hayashi M, Satoh N, Nishitani T, Shikano Y, Shimamoto K. Possible impairment of transcardiac utilization of adiponectin in patients with type 2 diabetes. Diabetes Care 2004;27:2217-2221.
60. Saino A, Pomidossi G, Perondi R, Morganti A, Turolo L, Mancia G. Modulation of sympathetic coronary vasoconstriction by cardiac renin-angiotensin system in human coronary heart disease. Circulation 2000;101: 2277-2283.
61. Remme WJ, de Leeuw PW, Bootsma M, Look MP, Kruijssen DA. Systemic neurohumoral activation and vasoconstriction during pacing-induced acute myocardial ischemia in patients with stable angina pectoris. Am J Cardiol 1991;68:181-186.
62. Foult JM, Tavolaro O, Antony I, Nitenberg A. Coronary vasodilation induced by intracoronary enalaprilat: an argument for the role of a local renin-angiotensin system in patients with dilated cardiomyopathy. Eur Heart J 1989;10:97-100.
63. Brunner-La Rocca HP, Esler MD, Jennings GL, Kaye DM. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J 2001;22:1136-1143.
64. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-372.
65. Golino P, Ravera A, Ragni M, Cirillo P, Piro O, Chiariello M. Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes. Circulation 2003;108:2864-2869.
66. Mizuno O, Hojo Y, Ikeda U, Katsuki T, Fukazawa H, Kurosaki K, Fujikawa H, Shimada K. Assessment of coagulation and platelet activation in coronary sinus blood induced by transcatheter coronary intervention for narrowing of the left anterior descending coronary artery. Am J Cardiol 2000;85:154-160.
67. Mizuno O, Ikeda U, Hojo Y, Fujikawa H, Katsuki T, Shimada K. Tissue factor expression in coronary circulation as a prognostic factor for late restenosis after coronary angioplasty. Cardiology 2001;95:84-89.
68. Fornitz GG, Nielsen P, Amtorp O, Kassis E, Abildgard U, Sloth C, Winther K, Orskov H, Dalsgard J, Husted S. Impaired fibrinolysis determines the outcome of percutaneous transluminal coronary angioplasty (PTCA). Eur J Clin Invest 2001;31:586-592.
69. Celermajer DS. Non invasive detection of atherosclerosis. N Engl J Med 1998; 339:2014-2015.
70. Patel PB, Pfau SE, Cleman MW, Brennan JJ, Howes C, Remetz M, Cabin HS, Setaro JF, Rinder HM. Comparison of coronary artery specific leukocyte-platelet conjugate formation in unstable versus stable angina pectoris. Am J Cardiol 2004;93:410-413.
71. Mazzone A, De Servi S, Ricevuti G, Mazzucchelli I, Fossati G, Pasotti D, Bramucci E, Angoli L, Marsico F, Specchia G. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation 1993;88:358-363.
72. Mueller HS, Rao PS, Greenberg MA, Buttrick PM, Sussman II, Levite HA, Grose RM, Perez-Davila V, Strain JE, Spaet TH. Systemic and transcardiac platelet activity in acute myocardial infarction in man: resistance to prostacyclin. Circulation 1985;72:1336-1345.
73. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
74. Neri Serneri GG, Boddi M, Coppo M, Chechi T, Zarone N, Moira M, Poggesi L, Margheri M, Simonetti I. Evidence for the existence of a functional cardiac renin-angiotensin system in humans. Circulation 1996;94:1886-1893.
75. Neri Serneri GG, Boddi M, Modesti PA, Coppo M, Cecioni I, Toscano T, Papa ML, Bandinelli M, Lisi GF, Chiavarelli M. Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Circ Res 2004;94:1630-1637.
76. Yeh ET, Anderson HV, Pasceri V, Willerson JT. C-reactive protein: linking inflammation to cardiovascular complications. Circulation 2001;104:974-975.
77. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-1818.
78. Moukarbel GV, Arnaout MS, Alam SE. C-reactive protein is a marker for a complex culprit lesion anatomy in unstable angina. Clin Cardiol 2001;24:506-510.
79. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, Ellis SG. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003;107:1750-1756.
80. Cusack MR, Marber MS, Lambiase PD, Bucknall CA, Redwood SR. Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol 2002;39:1917-1923.
81. Neumann FJ, Ott I, Gawaz M, Richardt G, Holzapfel H, Jochum M, Schomig A. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995;92:748-755.
82. Maier W, Altwegg LA, Corti R, Gay S, Hersberger M, Maly FE, Sutsch G, Roffi M, Neidhart M, Eberli FR, Tanner FC, Gobbi S, von Eckardstein A, Luscher TF. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid a but decreased C-reactive protein. Circulation 2005;111:1355-1361.
83. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002;347:5-12.
84. AHA. http://www.americanheart.org (accessed 21/6/05).
85. Luscher TF, Barton M. Biology of the endothelium. Clin Cardiol 1997;20:II3-II10.
86. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000-1006.
87. Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005;105:526-532.
88. Lazar HL, Haan CK, Yang X, Rivers S, Bernard S, Shemin RJ. Reduction of infarct size with coronary venous retroperfusion. Circulation 1992;86:352-357.
89. Sakai K, Yamagata T, Teragawa H, Matsuura H, Chayama K. Preconditioning effect during coronary angioplasty in patients with stable angina pectoris. Intern Med 2002;41:509-515.
90. Rastan AJ, Bittner HB, Gummert JF, Walther T, Schewick CV, Girdauskas E, Mohr FW. On-pump beating heart versus off-pump coronary artery bypass surgery - evidence of pump-induced myocardial injury. Eur J Cardiothorac Surg 2005;27:1057-1064.
91. Berland J, Farcot JC, Barrier A, Dellac A, Gamra H, Letac B. Coronary venous synchronized retroperfusion during percutaneous transluminal angioplasty of left anterior descending coronary artery. Circulation 1990;81:35-42.
92. British Cardiovascular Intervention Society (BCIS) Database, Audit. 2001; http://www.bcis.orgbcis.org (accessed 21/6/05).
93. Betriu A, Masotti M, Serra A, Alonso J, Fernandez-Aviles F, Gimeno F, Colman T, Zueco J, Delcan JL, Garcia E, Calabuig J. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol 1999;34:1498-1506.
94. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P. A comparison of balloon expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N Engl J Med 1994;331:489- 495.
95. Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V, Louvard Y, Desmedt B, Di Mario C, Leon MB. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004;109:1244-1249.
96. Roubin GS, Cannon AD, Agrawal SK, Macander PJ, Dean LS, Baxley WA, Breland J. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992;85:916-927.
97. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. N Engl J Med 1994;331:496- 501.
98. Hearn JA, King SB III, Douglas JSJ, Carlin SF, Lembo NJ, Ghazzal ZM. Clinical and angiographic outcomes after coronary artery stenting for acute or threatened closure after percutaneous transluminal coronary angioplasty: initial results with a balloon-expandable, stainless steel design. Circulation 1993;88:2086-2096.
99. US Food and Drug Administration. FDA Public health web notification: information for physicians on subacuet thrombosis (SAT) and hypersensitivity reaction with the use of the Cordis CYPHER corobary stent; 2003. http://www.fda.govcdphsafetycypher.html.
100. Tashiro H, Shimokawa H, Sadamatsu K, Aoki T, Yamamoto K. Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty. Coron Artery Dis 2001;12:107-113.
101. Ikeda U, Ito T, Shimada K. Interleukin-6 acute coronary syndrome. Clin Cardiol 2001;24:701-704.
102. Goel PK, Shahi M, Agarwal AK, Srivastava S, Seth PK. Platelet aggregability and occurrence of restenosis following coronary angioplasty. Int J Cardiol 1997;60:227-231.
103. Prisco D, Fedi S, Antonucci E, Capanni M, Chiarugi L, Chioccioli M, Falai M, Giglioli C, Abbate R, Gensini GF. Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA. Thromb Res 2001;104:181-186.
104. Inoue T, Sakai Y, Morooka S, Hayashi T, Takayanagi K, Takabatake Y. Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1996;28:1127-1133.
105. Oltrona L, Eisenberg PR, Lasala JM, Sewall DJ, Shelton ME, Winters KJ. Association of heparin-resistant thrombin activity with acute ischaemic complications of coronary interventions. Circulation 1996;94:2064- 2071.
106. Lee JS, Feldman AM. Gene therapy for therapeutic myocardial angiogenesis: a promising synthesis of two emerging technologies. Nat Med 1998;4:739-742.
107. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischaemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998;97:645-650.
108. Rezaee M, Yeung AC, Altman P, Lubbe D, Takeshi S, Schwartz RS, Stertzer S, Altman JD. Evaluation of the percutaneous intramyocardial injection for local myocardial treatment. Catheter Cardiovasc Interv 2001;53:271-276.
109. Herity NA, Lo ST, Oei F, Lee DP, Ward MR, Filardo SD, Hassan A, Suzuki T, Rezaee M, Carter AJ, Yock PG, Yeung AC, Fitzgerald PJ. Selective regional myocardial infiltration by the percutaneous coronary venous route: a novel technique for local drug delivery. Catheter Cardiovasc Interv 2000;51:358-363.
110. Vicario J, Piva J, Pierini A, Ortega HH, Canal A, Gerardo L, Pfeiffer H, Campos C, Fendrich I, Novero R, Monti A. Transcoronary sinus delivery of autologous bone marrow and angiogenesis in pig models with myocardial injury. Cardiovasc Radiat Med 2002;3:91-94.
111. Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539-548.
112. Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M, Eng CM, Desnick RJ. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001;345:25-32.
113. Oesterle SN, Reifart N, Hauptmann E, Hayase M, Yeung AC. Percutaneous in situ coronary venous arterialization: report of the first human catheter-based coronary artery bypass. Circulation 2001;103:2539-2543.
114. Takase H, Toriyama T, Sugiyama M, Nakazawa A, Hayashi K, Goto T, Sugiura T, Ikeda K, Sato K, Ueda R, Dohi Y. Effect of nifedipine on C-reactive protein levels in the coronary sinus and on coronary blood flow in response to acetylcholine in patients with stable angina pectoris having percutaneous coronary intervention. Am J Cardiol 2005;95:1235-1237.
115. Nichols AB, Owen J, Grossman BA, Marcella JJ, Fleisher LN, Lee MM. Effect of heparin bonding on catheter-induced fibrin formation and platelet activation. Circulation 1984;70:843-850.
116. Guindi MM, Walley VM. Coronary sinus thrombosis: a potential complication of right heart catheterization. Can J Surg 1987;30:66-67.
117. Economopoulos GC, Michalis A, Palatianos GM, Sarris GE. Management of catheter-related injuries to the coronary sinus. Ann Thorac Surg 2003;76:112-116.
118. Chronos NA, Goodall AH, Wilson DJ, Sigwart U, Buller NP. Profound platelet degranulation is an important side effect of some types of contrast media used in interventional cardiology. Circulation 1993; 88 2035-2044.
119. Kabbani SS, Watkins MW, Holoch PA, Terrien EF, Sobel BE, Schneider DJ. Platelet reactivity in coronary ostial blood: a reflection of the thrombotic state accompanying plaque rupture and of the adequacy of anti-thrombotic therapy. J Thromb Thrombolysis 2001;12:171-176.
120. Craft JA, Masci PP, Roberts MS, Brighton TA, Garrahy P, Cox S, Marsh NA. Increased platelet-derived microparticles in the coronary circulation of percutaneous transluminal coronary angioplasty patients. Blood Coagul Fibrinolysis 2004;15:475-482.
121. Rauch U, Wolff UM, Schultheiss HP, Schwimmbeck PL. Leukocyte CD15 expression and platelet activation in the coronary sinus after coronary intervention. Pathophysiol Haemost Thromb 2003;33:109-115.
122. Johansen O, Brekke M, Seljeflot I, Semb AG, Arnesen H. Blood platelet count and reactivity are associated with restenosis 6 months after coronary angioplasty. Scand Cardiovasc J 2004;38:211-215.
123. Watkins MW, Luetmer PA, Schneider DJ, Witmer WT, Vaitkus PT, Sobel BE. Determinants of rebound thrombin activity after cessation of heparin in patients undergoing coronary interventions. Cathet Cardiovasc Diagn 1998;44:257-264.
124. Fornitz GG, Nielsen P, Amtorp O, Kassis E, Abildgard U, Sloth C, Winther K, Orskov H, Dalsgard J, Husted S. Impaired fibrinolysis determines the outcome of percutaneus transluminal coronary angioplasty (PTCA). Eur J Clin Invest 2001;31:586-592.
125. Mizuno O, Ikeda U, Hojo Y, Fujikawa H, Katsuki T, Shimada K. Tissue factor expression in coronary circulation as a prognostic factor for late restenosis after coronary angioplasty. Cardiology 2001;95:84-89.
126. Mizuno O, Hojo Y, Ikeda U, Katsuki T, Fukazawa H, Kurosaki K, Fujikawa H, Shimada K. Assessment of coagulation and platelet z-activation in coronary sinus blood induced by transcatheter coronary intervention for narrowing of the left anterior descending coronary artery. Am J Cardiol 2000;85:154-160.
127. Patel PB, Pfau SE, Cleman MW, Brennan JJ, Howes C, Remetz M, Cabin HS, Setaro JF, Rinder HM. Comparison of coronary artery specific leukocyte-platelet conjugate formation in unstable versus stable angina pectoris. Am J Cardiol 2004;93:410-413.